RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna Brown, Kenneth F. Bradstock, Peer Arts et al.|Blood Advances|2020Cited by 155
Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) FrameworkDanielle Blunt, Steven Lane, Sarah Finlayson et al.|Blood|2024Cited by 0